


Ulcerative Colitis Drug Market CAGR to be at 6.5% from 2025 to 2032 | \$14.79 Billion Industry Revenue by 2032 | Says CMI

Ulcerative Colitis Drug Market is estimated to valued USD 9.52 Bn in 2025 and expected reach USD 14.79 Bn by 2032, exhibiting CAGR of 6.5% from 2025 to 2032

BURLINGAME, CA, UNITED STATES,
November 19, 2025 /

EINPresswire.com/ -- [Ulcerative Colitis Drug Market](#) to Hit USD 9.52 Billion in 2025, Driven by Rising Disease Incidence



Therapeutic Innovations to Steer Global Market Past USD 14.79 Billion by 2032 at 6.5% CAGR – Coherent Market Insights

The Global Ulcerative Colitis Drug Market is estimated to be valued at USD 9.52 Bn in 2025 and is expected to reach USD 14.79 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.5% from 2025 to 2032. The ulcerative colitis drug market is increasingly driven by biologics and targeted therapies, which offer greater efficacy and better patient outcomes than traditional treatments. Personalized medicine — tailoring treatment based on individual biology — and rising R&D investment are fueling rapid innovation. Growing disease awareness and expanding healthcare infrastructure in emerging markets are also supporting sustained market growth.

Request a sample report at : <https://www.coherentmarketinsights.com/insight/request-sample/8592>

Request a sample report (Use Corporate eMail ID to Get Higher Priority) at:

Global Ulcerative Colitis Drug Market Key Takeaways

According to Coherent Market Insights (CMI), the global ulcerative colitis drug market size is estimated to total USD 9.52 Bn in 2025 and is expected to grow at a CAGR of 6.5% during the

forecast period, reaching USD 14.79 Bn by 2032.

Biologics segment dominates the ulcerative colitis market, capturing about 70.1% of the market share in 2025.

Based on drug class, aminosalicylates segment is slated to account for 23.2% of the global ulcerative colitis drug market share by 2025.

In terms of disease type, ulcerative proctitis is set to hold a market share of 34.2% in 2025.

North America is expected to dominate the global market, holding a share of 37.3% in 2025.

Asia Pacific, with an estimated share of 24.3% in 2025, is projected to emerge as a hotbed for ulcerative colitis drug manufacturers during the forecast period.

Rising Incidence of Ulcerative Colitis Fueling Market Growth

Coherent Market Insights' latest ulcerative colitis drug market analysis outlines major factors driving growth. Increasing prevalence of ulcerative colitis is one such prominent growth driver.

Chronic inflammatory bowel diseases like ulcerative colitis are becoming more common globally. This rising burden of ulcerative colitis is leading to a higher demand for ulcerative colitis drugs.

According to the article in The Lancet, the global prevalence of ulcerative colitis was estimated at around 5 million people as of 2023. This number is expected to rise further, thereby stimulating ulcerative colitis drug market growth during the forecast period.

Request for Customization : <https://www.coherentmarketinsights.com/insight/request-customization/8592>

High Costs and Side Effects Limiting Ulcerative Colitis Drug Market Growth

The global ulcerative colitis drug market outlook indicates steady future growth. However, side effects and high costs of advanced therapies are expected to limit market expansion to some extent during the forecast period.

Advanced treatments like biologics and novel small-molecule drugs are quite expensive. This limits their accessibility, especially in low- and middle-income regions, thereby reducing overall ulcerative colitis drug market demand.

In addition, long-term use of some therapeutics can cause side effects like infections and immunosuppression. These safety concerns could deter physicians and patients from adopting more aggressive or newer therapies, thereby slowing down market growth.

Ongoing Therapeutic Innovations Creating Lucrative Growth Avenues

Continuous research and development have led to the introduction of novel drug classes, including JAK inhibitors (e.g., tofacitinib, upadacitinib), S1P modulators (e.g., ozanimod), and next-generation biologics. These novel therapeutics enhance treatment outcomes as well as improve patient quality of life.

For instance, in September 2025, the U.S. FDA approved TREMFYA (guselkumab) for subcutaneous induction in adults with ulcerative colitis. Such innovations are expected to create lucrative growth opportunities for ulcerative colitis drug manufacturers during the forthcoming period.

Emerging Global Ulcerative Colitis Drug Market Trends

Rise of biosimilars is a key growth-shaping trend in the ulcerative colitis drug market. Biosimilars of anti-TNF agents like infliximab and adalimumab are gaining popularity due to their cost-effectiveness, improving access to treatment and boosting overall ulcerative colitis drug market value.

Growing awareness and earlier diagnosis are expected to boost sales of ulcerative colitis drugs during the forecast period. Awareness campaigns and improved diagnostic technologies like colonoscopy and biomarkers have led to earlier detection and intervention, fueling ulcerative colitis drug demand.

Rising adoption of biologics is another emerging market trend. There is a shift from conventional therapies like aminosalicylates and corticosteroids toward biologics and targeted small molecules, driven by higher efficacy and improved long-term disease management. This transition is expected to boost growth of the ulcerative colitis drug market during the forecast period.

Competitor Insights

Key companies in the ulcerative colitis drug market report:

Johnson & Johnson (Janssen Biotech)

AbbVie Inc.

Pfizer Inc.

Eli Lilly and Company

Takeda Pharmaceutical Company Limited

Bristol Myers Squibb Company

Amgen Inc.

Novartis AG

Gilead Sciences Inc.
Celltrion Healthcare Co Ltd
Merck & Co Inc.
Hoffmann-La Roche Ltd
Biogen Inc.
Eisai Co Ltd
Boehringer Ingelheim International GmbH
Key Developments

In October 2025, Merck started Phase 2b trials of Tulisokibart for three new inflammatory diseases. The drug is now being studied in six diseases, including ulcerative colitis and Crohn's disease.

In September 2024, Johnson & Johnson received the U.S. FDA approval of TREMFYA for the treatment of ulcerative colitis in adults. It is the first fully human antibody approved for ulcerative colitis that blocks IL-23 in two ways.

In June 2024, the U.S. FDA approved SKYRIZI (risankizumab-rzaa) for moderately to severely active ulcerative colitis in adults. This approval expands AbbVie's portfolio across IBD.

Buy The Latest Version Of the Reports with an Impressive Discount (Up to 25% Off) at:
<https://www.coherentmarketinsights.com/insight/buy-now/8592>

Author of this Marketing PR:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

About CMI:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has excelled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Raj Shah
Coherent Market Insights Pvt. Ltd.
+1 252-477-1362
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/868467064>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.